ITBS in MCI and Mild AD

Last updated: October 31, 2024
Sponsor: National Defense Medical Center, Taiwan
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Dementia

Memory Loss

Mild Cognitive Impairment

Treatment

Active rTMS

Sham rTMS

Clinical Study ID

NCT06670820
A202305164
  • Ages 50-85
  • All Genders

Study Summary

This study aims to examine the effects of iTBS on cognitive function in individuals with MCI or mild AD, with a secondary objective of exploring prefrontal TBS mechanisms for cognitive function and the effect of iTBS on BDNF.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Clinical diagnosis of MCI (overall Clinical Dementia Rating of 0.5)

  • Clinical diagnosis of mild Alzheimer's Disease (overall Clinical Dementia Rating of 0.5 or 1)

Exclusion

Exclusion Criteria:

  • History of stroke

  • History of uncontrol seizure

  • History of significant head trauma followed by persistent neurologic deficit orknown structural brain abnormality

  • Mental illness

  • Drug abuse

Study Design

Total Participants: 80
Treatment Group(s): 2
Primary Treatment: Active rTMS
Phase:
Study Start date:
October 31, 2024
Estimated Completion Date:
December 31, 2028

Connect with a study center

  • Tri-Service General Hospital

    Taipei, Other 114
    Taiwan

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.